Canopy Growth Corp (CGC)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
CGC
Canopy Growth Corp
$0.93
-0.25%
HEALTHCARE · Cap: $416.81M
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.26
+0.83%
HEALTHCARE · Cap: $58.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1572925% more annual revenue ($4.62T vs $293.63M). TAK leads profitability with a -3.5% profit margin vs -79.2%. TAK earns a higher WallStSmart Score of 53/100 (C-).
CGC
Hold36
out of 100
Grade: F
TAK
Buy53
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -37.6% — below average capital efficiency
Negative free cash flow — burning cash
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : CGC
The strongest argument for CGC centers on Price/Book. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.43 suggests the stock is reasonably priced for its growth.
Bear Case : CGC
The primary concerns for CGC are EPS Growth, Market Cap, Return on Equity.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
CGC carries more volatility with a beta of 2.43 — expect wider price swings.
CGC is growing revenue faster at 12.5% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TAK scores higher overall (53/100 vs 36/100) and 10.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Canopy Growth Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. The company is headquartered in Smiths Falls, Canada.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?